Nang Kuang Pharmaceutical Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Yu-Bei Wang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 3.5% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings
Nov 19
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings
May 22Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings
Apr 02Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet
Mar 20Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Mar 03Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?
Feb 13
Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years
Jan 26Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)
Jan 08Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend
Nov 29CEO
Yu-Bei Wang
no data
Tenure
Ms. Yu-Bei Wang serves as General Manager of Nang Kuang Pharmaceutical Co., Ltd. She co-founded Nang Kuang Pharmaceutical Company in 1963 and served as its General Manager. Ms. Wang serves as a Director of...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nang Kuang Pharmaceutical Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Yuan Lu | KGI Securities Co. Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |